2026 Dyslipidemia Guidelines Redefine Treatment, Monitoring Strategies, With Roger Blumenthal, MD

The updated dyslipidemia guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other organizations, have redefined lipid management as a more unified and aggressive prevention-focused strategy across all ages.^1,2

Roger Blumenthal, MD, director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and Kenneth Jay Pollin Professor of Cardiology at Johns Hopkins Medicine, discussed the updated guidelines for both the US and Europe at the 10th Annual Heart in Diabetes Meeting in Philadelphia, PA.

“Essentially, we made it much easier for clinicians and patients to justify making an effort to comprehensively improve dietary and exercise habits,” Blumenthal told HCPLive in an exclusive interview. “But, after a period of time, if they can’t reach their lipid goals, then we make it easier to qualify for the use of medication to get to those targets.”

The ACC/AHA guidelines, published in March 2026, reemphasized the importance of early intervention in dyslipidemia. By implementing health behavior counseling in youth, clinicians can significantly reduce a patient’s likelihood of cardiovascular disease down the line. Specifically, the document suggests that clinicians consider pharmacotherapy in adolescents with familial hypercholesterolemia (FH) and young adult patients with LDL-C ≥160 mg/dL, as well as those with a strong family history of premature atherosclerotic cardiovascular disease (ASCVD).¹

Additionally, the guidelines highlighted the PREVENT equations, reestablishing them after years of suggesting the less specific Pooled Cohort Equations (PCE). The PCE were derived from roughly 25,000 patients, with some from older birth cohorts; the PREVENT equations, meanwhile, were developed from >3,000,000 individual patients from both population-based and clinical datasets. The significantly greater specificity of the PREVENT equations motivated the shift back after years of promoting PCE.¹

Another key factor in the updated guidelines is the increased focus on LDL-C-lowering therapy, with LDL-C and non-HDL-C treatment goals once more at the forefront of lipid-lowering therapy. Prior to the release of this document, percentage reduction in LDL-C was the cornerstone of lipid-lowering therapy – while it still remains a priority, it is once again in a back seat to the more specific and informative LDL-C goals measurement.¹

The guidelines also substantially support the measurement of lipoprotein(a) and apolipoprotein B (ApoB) to determine ASCVD risk and to guide therapy following the achievement of LDL-C goals, respectively. Lipoprotein(a) is considered a risk-enhancing factor in many patients, and its elevation should warrant more intensified lowering of LDL-C. Additionally, ApoB serves as a secondary marker to prevent missing adult patients with residual elevated lipoprotein-related risk that could be underrepresented by standard lipid profiles.¹

“If a patient knows that they’re at much higher risk, they’re going to change their priorities. They’re going to make time to exercise three or four times a week, rather than once a week,” Blumenthal said. “They’ll really put the emphasis on eating more fruits and vegetables, seafood, less of the sweets and fried foods. Knowledge is power, and if we can motivate people, that will be the secret to lowering their long-term risk of heart attack and stroke.”

Editors’ Note: Blumenthal reports no relevant disclosures.

References

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17). doi:10.1161/cir.0000000000001423

2. Abuhalimeh B, Alhmouz M, Behrooz L, et al. Implications of the 2026 ACC/AHA/Multiscoeity Dyslipidemia Guideline for Lipid Management in Vascular Disease. American College of Cardiology. June 16, 2026. Accessed June 30, 2026. https://www.acc.org/latest-in-cardiology/articles/2026/06/15/14/16/implications-of-the-2026-multisociety-dyslipidemia-guideline